Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data

BACKGROUND: Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes. METHODS: This is a post-hoc analysis of an open-label, long-term (up t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nijs, Michel, Wajs, Ewa, Aluisio, Leah, Turkoz, Ibrahim, Daly, Ella, Janik, Adam, Borentain, Stephane, Singh, Jaskaran B, DiBernardo, Allitia, Wiegand, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387766/
https://www.ncbi.nlm.nih.gov/pubmed/32270176
http://dx.doi.org/10.1093/ijnp/pyaa027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387766/
https://www.ncbi.nlm.nih.gov/pubmed/32270176
http://dx.doi.org/10.1093/ijnp/pyaa027

Ejemplares similares